ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
1-Year Return
26.77%
This Quarter Return
+12.23%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$597M
AUM Growth
+$99.9M
(+20%)
Cap. Flow
+$40.6M
Cap. Flow
% of AUM
6.81%
Top 10 Holdings %
Top 10 Hldgs %
54.95%
Holding
336
New
84
Increased
77
Reduced
72
Closed
71
Top Buys
| 1 |
Immunovant
IMVT
|
$18.7M |
| 2 |
Ascendis Pharma
ASND
|
$16.4M |
| 3 |
Zura Bio
ZURA
|
$15.3M |
| 4 |
Zai Lab
ZLAB
|
$12.3M |
| 5 |
AAM
AA Mission Acquisition Corp.
AAM
|
$10.1M |
Top Sells
| 1 |
Protagonist Therapeutics
PTGX
|
$28M |
| 2 |
Roivant Sciences
ROIV
|
$13M |
| 3 |
Edgewise Therapeutics
EWTX
|
$11.2M |
| 4 |
Merck
MRK
|
$8.47M |
| 5 |
TECX
Tectonic Therapeutic, Inc. Common Stock
TECX
|
$6.96M |
Sector Composition
| 1 | Healthcare | 88.63% |
| 2 | Financials | 3.75% |
| 3 | Communication Services | 0.59% |
| 4 | Utilities | 0.21% |
| 5 | Technology | 0.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
201
Direxion Daily S&P Biotech Bear 3X Shares
LABD
$57.1M
| $49.1K | 0.01% |
+8,400
| New | +$49.1K |
|
202
89bio
ETNB
$1.3B
| $48.5K | 0.01% |
6,560
+1,000
| +18% | +$7.4K |
|
203
FibroGen
FGEN
$48.7M
| $48.2K | 0.01% |
+4,827
| New | +$48.2K |
|
|
JWN
204
DELISTED
Nordstrom
JWN
| $45K | 0.01% |
+2,000
| New | +$45K |
|
205
Celcuity
CELC
$2.39B
| $44.7K | 0.01% |
3,000
+1,600
| +114% | +$23.9K |
|
206
Ovid Therapeutics
OVID
$86M
| $44.5K | 0.01% |
37,743
+18,553
| +97% | +$21.9K |
|
207
Ardelyx
ARDX
$1.59B
| $44.1K | 0.01% |
6,400
-63,600
| -91% | -$438K |
|
208
Milestone Pharmaceuticals
MIST
$151M
| $42.5K | 0.01% |
27,931
-174,529
| -86% | -$265K |
|
|
MREO
209
Mereo BioPharma
MREO
$280M
| $41.1K | 0.01% |
10,000
-45,400
| -82% | -$187K |
|
210
Ultra Clean Holdings
UCTT
$1.1B
| $39.9K | 0.01% |
1,000
| – | – |
|
211
Veru
VERU
$49.4M
| $39.2K | 0.01% |
+5,100
| New | +$39.2K |
|
|
LUMO
212
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| $38.7K | 0.01% |
+10,000
| New | +$38.7K |
|
213
Pharvaris
PHVS
$1.49B
| $37K | 0.01% |
2,000
| – | – |
|
214
Pyxis Oncology
PYXS
$111M
| $36.7K | 0.01% |
10,000
| – | – |
|
215
Forte Biosciences
FBRX
$139M
| $33.5K | 0.01% |
6,000
-370
| -6% | -$2.07K |
|
216
IDEAYA Biosciences
IDYA
$2.34B
| $31.7K | 0.01% |
1,000
+700
| +233% | +$22.2K |
|
|
AAM.WS
217
AA Mission Acquisition Corp. Warrants, each whole warrant entitles the holder to purchase one Class A ordinary share at a price of $11.50 per share
AAM.WS
| $30.3K | ﹤0.01% |
+505,099
| New | +$30.3K |
|
218
Bausch Health
BHC
$2.71B
| $30.2K | ﹤0.01% |
+3,700
| New | +$30.2K |
|
219
NCR Atleos
NATL
$2.95B
| $28.5K | ﹤0.01% |
1,000
| – | – |
|
220
Ionis Pharmaceuticals
IONS
$9.79B
| $28K | ﹤0.01% |
700
-800
| -53% | -$32K |
|
221
Avidity Biosciences
RNA
$6.41B
| $27.6K | ﹤0.01% |
+600
| New | +$27.6K |
|
222
NCR Voyix
VYX
$1.82B
| $27.1K | ﹤0.01% |
2,000
| – | – |
|
223
Perrigo
PRGO
$3.13B
| $26.2K | ﹤0.01% |
1,000
-100
| -9% | -$2.62K |
|
224
Neurogene
NGNE
$286M
| $23.2K | ﹤0.01% |
553
-700
| -56% | -$29.4K |
|
225
Krystal Biotech
KRYS
$4.37B
| $18.2K | ﹤0.01% |
+100
| New | +$18.2K |
|